source
- Contraline secures $92.5M Series B to fund Phase 3 trial of male contraceptive gelContraline, a startup developing a male contraceptive, announced it has closed a Series B financing round worth $92.5 million. The capital will be used to advance its candidate, referred to as NES…
- Travere Therapeutics pays $112 million upfront to China’s Everest Medicines to expand rare kidney disease pipelineTravere Therapeutics, a San Diego‑based biotech, announced a partnership with China‑based Everest Medicines to strengthen its rare kidney disease portfolio beyond its approved drug Filspari. Under…